Publication: Colorimetric detection of PCA3 in urine for prostate cancer diagnosis using thiol-labeled PCR primer and unmodified gold nanoparticles
1
Issued Date
2019-01-01
Resource Type
ISSN
18733492
00098981
00098981
Other identifier(s)
2-s2.0-85055860640
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinica Chimica Acta. Vol.488, (2019), 40-49
Suggested Citation
Khin Phyu Pyar Htoo, Vichanan Yamkamon, Sakda Yainoy, Thummaruk Suksrichavalit, Wit Viseshsindh, Warawan Eiamphungporn Colorimetric detection of PCA3 in urine for prostate cancer diagnosis using thiol-labeled PCR primer and unmodified gold nanoparticles. Clinica Chimica Acta. Vol.488, (2019), 40-49. doi:10.1016/j.cca.2018.10.036 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/50362
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Colorimetric detection of PCA3 in urine for prostate cancer diagnosis using thiol-labeled PCR primer and unmodified gold nanoparticles
Abstract
© 2018 Elsevier B.V. Background: PCA3, a non-coding RNA, has been approved as a potential urinary biomarker for prostate cancer. However, PCA3 urine tests have some limitations. Therefore, we developed a colorimetric method for PCA3 detection in urine. Methods: The assay was based on interactions between unmodified gold nanoparticles (AuNPs) and thiolated PCR products. Thiolated PCR products were amplified by RT-PCR using a thiol-labeled primer at the 5′ end. Thiolated products of PCA3 bound to the surface of AuNPs and led to the prevention of salt-induced aggregation (red color). In the absence of the PCR products, AuNPs changed their color from red to blue due to the salt-induced aggregation. These changes were detected by the naked eye and spectrophotometer. Results: Our assay was specific for PCA3 in prostate cancer cell lines with a visual detection limit of 31.25 ng/reaction. The absorption ratio 520/640 nm was linear against PCR product concentration (R 2 = 0.9798) in the reaction. This method is promising for discrimination of prostate cancer patients from both healthy controls and benign prostatic hyperplasia patients according to their urinary PCA3 expression levels. Conclusions: This study established a simple, rapid, sensitive and specific assay for PCA3 detection which may be applicable for prostate cancer diagnosis.